Novartis psoriasis prospect tops J&J's fast-growing Stelara in PhIII

Johnson & Johnson's ($JNJ) Stelara has been cruising lately, most recently posting a 46.8% sales leap in Q3 for the New Jersey pharma giant. But it's got some psoriasis competition waiting in the wings: On Friday, Novartis ($NVS) announced its Phase III prospect, nearing approval after October's unanimous recommendation from an FDA advisory committee, had bested Stelara in a head-to-head trial, reducing psoriasis symptoms by 90%. Report | More